In Vivo Mechanism by Which Leflunomide Controls Lymphoproliferative and Autoimmune Disease in MRL/MpJ-lpr/lpr Mice

Journal of Immunology

Volumn 159, Issue 1, 1997, Pages 167-174

  Xu, Xiulong ^b   Blinder, Leonard ^b   Shen, Jikun ^b   Gong, Haihua ^b   Finnegan, Alison ^b   Williams, James W ^b   Chong, Anita S F ^a  

^a RUSH MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE DERIVATIVE; DIHYDROOROTATE DEHYDROGENASE; HYDROXYBUTYRIC ACID; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; LEFLUNOMIDE; OXIDOREDUCTASE; PYRIMIDINE NUCLEOTIDE; TERIFLUNOMIDE; URIDINE;

ANIMAL; ARTICLE; AUTOIMMUNE DISEASE; DRUG ANTAGONISM; LYMPH NODE; LYMPHOPROLIFERATIVE DISEASE; METABOLISM; MOUSE; MOUSE MUTANT;

ANILINE COMPOUNDS; ANIMALS; AUTOIMMUNE DISEASES; HYDROXYBUTYRATES; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LYMPH NODES; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, MUTANT STRAINS; OXIDOREDUCTASES; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PYRIMIDINE NUCLEOTIDES; URIDINE;

EID: 0031180972     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bartlett, R., M. Dimitrijevic, T. Mattar, T. Germann, E. Rüde, G. Thoenes, C. Küchle, H.-U. Schorlemmer, E. Bremer, A. Finnegan, and R. Schleyerbach. 1991. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Action 32:10.
2. Bartlett, R., G. Campion, P. Musikic, R. Schleybach, T. Zelinski, and H.-U. Schorlemmet. 1994. Leflunomide: a novel immunomodulating drug. In Nonsteroidal Anti-Inflammatory Drugs: Mechanisms and Clinical Uses. A. J. Lewis and D. E. Furst, eds. Marcel Dekker Inc., New York, p. 349.
3. McChesney, L., F. Xiao, H. Sankary, P. Foster, S. Sharman, and M. Haklin. 1994. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 57:57.
4. Xiao, F., A. Chong, P. Foster, H. Sankary, L. McChesney, G. Koukoulis. J. Yang, D. Frieders, and J. Williams. 1994. Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation 58:828.
5. Xiao, F., A. Chong, J. Shen, J. Yang, J. Short, P. Foster, H. Sankary, S. Jensik, D. Mital, L. McChesney, G. Kuokoulis, and J. Williams. 1995. Pharmacologically induced regression of chronic transplant rejection. Transplantation 60:1065.
6. Williams, J., F. Xiao, P. Foster, C. Clardy, L. McChesney, H. Sankary, and A. Chong. 1994. Leflunomide in experimental experimental transplantation: control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 57:1223.
7. Mladenovic, V., Z. Domljan, B. Rozman, I. Jajic, D. Mihajlovic, J. Dordevic, M. Popovic, M. Dimitrijevic, M. Zivkovic, and G. Campion. 1995. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 38:1595.
8. Xu, X., J. Williams, H. Gong, A. Finnegan, and A. Chong. 1996. Two activities of the immunosuppressive metabolite of leflunomide, A771726: inhibition of pyrimidine synthesis and protein tyrosine phosphorylation. Biochem. Pharmacol. 52:527.
9. Williamson, R., C. Yea, P. Robson, A. Curnock, S. Gadhert, A. Hambleton, K. Woodwar, J.-M. Bruneau, P. Hambleton, D. Moss, T. A. Thomson, S. Spinella-Jaegle, et al. 1995. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. 270:22467.
10. Greene, S., K. Watanabe, J. Braatz-Trulson, and L. Lou. 1995. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent, leflunomide, Biochem. Pharmacol. 50:861.
11. Cherwinski, H., R. Cohn, P. Cheung, D. Webster, Y. Xu, J. Caulfield, J. Young, G. Nakano, and J. Ransom. 1995. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J. Pharmacol. Exp. Ther. 275:1043.
12. Cherwinski, H., N. Byars, G. Ballaron, G. Nakano, J. Young, and J. Ransom. 1995. Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm. Res. 44:317.
13. Davis, J., G. Cain, W. Pitts, R. Magolda, and R. Copeland. 1996. The immuno-suppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35:1270.
14. Mattar, T., K. Kochar, R. Bartlett, E. Bremer, and A. Finnegan. 1993. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. 334:161.
15. Xu, X., J. W. Williams, E. G. Bremer, A. Finnegan, and A. S.-F. Chong. 1995. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J. Biol. Chem. 270:12398.
16. Cohen, P., and R. Eisenberg. 1991. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9:243.
17. Watanabe-Fukunaga, R., C. Brannan, N. Copeland, N. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by efects in Fas antigen that mediates apoptosis. Nature 356:314.
18. Alderson, M., T. Tough, T. Davis-Smith, S. Braddy, B. Falk, K. Schooley, R. Goodwin, C. Smith, K. Ramsdell, and D. Lynch. 1995. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181:71.
19. Russell, J., B. Rush, C. Weaver, and R. Wang. 1993. Mature T cell of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc. Natl. Acad. Sci. USA 90:4409.
20. Singer, G., and A. Abbas. 1994. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1:365.
21. Nagata, S., and T. Suda. 1995. Fas and Fas ligand: lpr and gld mutations. Immunol. Today 16:39.
22. Roark, J., C. Kuntz, K.-A. Nguyen, L. Mandik, M. Cattermole, and J. Erikson. 1995. B cell selection and allelic exclusion of an anti-DNA Ig transgene in MRL-lpr/lpr mice, J. Immunol. 154:4444.
23. Davignon, J., R. Budd, R. Ceredig, P. Piguet, H. MacDonald, J. Cerottini, P. Vassalli, and S. Izui. 1985. Functional analysis of T cell subsets from mice bearing the lpr gene. J. Immunol. 135:2423.
24. Altman, A., A. Theofilopoulous, R. Weiner, D. Kutz, and F. Dixon. 1981. Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J. Exp. Med. 154:791.
25. Samelson, L., W. Davidson, H. Morse, and R. Klausner. 1986. Abnormal tyrosine phosphorylation on T cell receptor in lymphoproliferative disorders. Nature 324: 674.
26. fyn in CD4-CD8-T cells of mice with a lymphoproliferative disorder. Proc. Natl. Acad. Sci. USA 86:10064.
27. Eaton, R., G. Schneider, and P. Schur. 1983. Enzyme immunoassay for antibodies to native DNA: specificity and quality of antibodies. Arthritis Rheum. 261:52.
28. Peters, G., J. Nadal, E. Laurensse, D. de Kant, and H. Pinedo. 1990. Retention of in vivo antipyrimidine effects of brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer. Biochem. Pharmacol. 30:135.
29. Fairbanks, L., M. Bofill, K. Ruckemann, and H. Simmonds. 1995. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. J. Biol. Chem. 270:29682.
30. Elder, R., X. Xu, J. Williams, H. Gong, A. Finnegan, and A. Chong. 1997. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J. Immunol. 159:22.
31. Chong, A.-F., K. Rezai, H. Gebel, A. Finnegan, P. Foster, X. Xu, and J. Williams. 1996. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 61:140.
32. Siemasko, K., A.-F. Chong, J. Williams, E. Bremer, and A. Finnegan. 1996. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 61:635.
33. Karle, J., L. Anderson, D. Dietrick, and R. Cysyk. 1991. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice. Cancer Res. 41:4952.
34. Moyer, J., J. Oliver, and R. Handschumacher. 1981. Salvage of circulating pyrimidine nucleosides in the rat. Cancer Res. 41:3010.
35. Lemay, S., C. Mao, and A. Singh. 1996. Cytokine gene expression in the MRL/ lpr model of lupus nephritis. Kidney Int. 50:85.
36. Simon, P., R. Townsend, R. Harris, E. Jones, and B. Jaffee. 1993. Brequinar sodium: inhibition of dihydroorotic acid dehydrogenase, depletion of pyrimidine pools and consequent inhibition of immune functions in vitro. Transplant. Proc. 25:(Suppl. 2):77.
37. Makowka, L., L. Sher, and D. Cramer. 1993. The development of brequinar as an immunosuppressive drug for transplantation. Immunol. Rev. 136:51.
38. Webster, D., D. M. O. Becroft, and D. Suttle, 1960. Hereditary orotic aciduria and other disorders of pyrimidine metabolism, In The Metabolic and Molecular Bases of Inherited Disease. C. Scriver, A. Beaudet, W. Sly, and D. Valle, eds. McGraw-Hill, New York, p. 1799.
39. Chan, A., T. Kadlecek, M. Elder, A. Filipovich, W. Kuo, M. Iwashima, T. Parslow, and A. Weiss. 1994. ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science 264:1599.
40. fyn. Cell 70:751.
41. lck. Eur. J. Immunol. 25:3155.